publication . Article . 2012

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Laia Bruni; BEATRIZ SERRANO CARRO; Sara Tous; FRANCESC XAVIER BOSCH JOSÉ;
Open Access English
  • Published: 01 Dec 2012 Journal: Infectious Agents and Cancer (issn: 1750-9378, Copyright policy)
  • Publisher: BMC
  • Country: Spain
Abstract
<p>Abstract</p> <p>Background</p> <p>Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development.</p> <p>Methods</p> <p>Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World P...
Subjects
Medical Subject Headings: female genital diseases and pregnancy complications
free text keywords: Papil·lomavirus, Càncer de coll uterí, Papillomaviruses, Cervix cancer, Human papillomavirus, Cervical cancer, Genotype, Epidemiology, Human papillomavirus vaccines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Infectious and parasitic diseases, RC109-216, Research Article, Cancer Research, Oncology, Infectious Diseases
37 references, page 1 of 3

Ferlay, J, Shin, HR, Bray, F, Forman, D, Mathers, C, Parkin, DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010

Walboomers, JM, Jacobs, MV, Manos, MM, Bosch, FX, Kummer, JA, Shah, KV, Snijders, PJ, Peto, J, Meijer, CJ, Muñoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189 (1): 12-19 [OpenAIRE] [PubMed] [DOI]

Vol 100, A Review of Human Carcinogens. Part B: Biological Agents. 2011

Human papillomavirus vaccines WHO position paper. 2009

Stanley, M. HPV - immune response to infection and vaccination. Infect Agent Cancer. 2010; 5: 19 [OpenAIRE] [PubMed] [DOI]

Li, N, Franceschi, S, Howell-Jones, R, Snijders, PJ, Clifford, GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128 (4): 927-935 [OpenAIRE] [PubMed] [DOI]

de Sanjose, S, Quint, WG, Alemany, L, Geraets, DT, Klaustermeier, JE, Lloveras, B, Tous, S, Felix, A, Bravo, LE, Shin, HR, Vallejos, CS, de Ruiz, PA, Lima, MA, Guimera, N, Clavero, O, Alejo, M, Llombart-Bosch, A, Cheng-Yang, C, Tatti, SA, Kasamatsu, E, Iljazovic, E, Odida, M, Prado, R, Seoud, M, Grce, M, Usubutun, A, Jain, A, Suarez, GA, Lombardi, LE, Banjo, A. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11 (11): 1048-1056 [OpenAIRE] [PubMed] [DOI]

Garland, SM, Steben, M, Sings, HL, James, M, Lu, S, Railkar, R, Barr, E, Haupt, RM, Joura, EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199 (6): 805-814 [OpenAIRE] [PubMed] [DOI]

Romanowski, B. Long-term protection against cervical infection with the human papillomavirus. Hum Vaccin. 2011; 7 (2): 161-169 [OpenAIRE] [PubMed] [DOI]

Kane, MA, Serrano, B, de Sanjose, S, Wittet, S. Implementation of HPV immunization in the developing world. Vaccine. 2012; 30 (Suppl 5): F192-200 [PubMed]

GAVI Alliance Press releases.

Kane, MA. Preventing Cancer with Vaccines: Progress in the Global Control of Cancer. Cancer Prev Res (Phila). 2012; 5 (1): 24-9 [PubMed] [DOI]

Kim, JJ, Brisson, M, Edmunds, WJ, Goldie, SJ. Modeling cervical cancer prevention in developed countries. Vaccine. 2008; 26 (Suppl 10): K76-86 [OpenAIRE] [PubMed]

Goldie, SJ, O'Shea, M, Diaz, M, Kim, SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters. 2008; 16 (32): 86-96 [PubMed] [DOI]

Brotherton, JM, Gertig, DM. Primary human prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Rev Anti Infect Ther. 2011; 9 (8): 627-39 [OpenAIRE] [PubMed] [DOI]

37 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue